Abcam (NASDAQ:ABCM – Get Rating) had its price target lifted by Royal Bank of Canada from GBX 1,700 ($20.54) to GBX 2,200 ($26.58) in a research report released on Wednesday, The Fly reports.
Separately, Panmure Gordon upgraded shares of Abcam from a hold rating to a buy rating in a report on Monday, September 5th.
Get Abcam alerts:Abcam Price Performance
Shares of ABCM stock opened at $16.17 on Wednesday. The firm has a fifty day moving average of $14.85 and a 200-day moving average of $15.54. Abcam has a 12-month low of $12.54 and a 12-month high of $24.00.
Institutional Investors Weigh In On Abcam
Several large investors have recently made changes to their positions in the stock. Advisor Group Holdings Inc. increased its holdings in Abcam by 20.5% during the fourth quarter. Advisor Group Holdings Inc. now owns 5,876 shares of the company's stock worth $138,000 after buying an additional 999 shares during the last quarter. TD Asset Management Inc. lifted its stake in Abcam by 63.0% in the fourth quarter. TD Asset Management Inc. now owns 72,773 shares of the company's stock valued at $1,714,000 after acquiring an additional 28,130 shares during the last quarter. Bank of Montreal Can lifted its stake in Abcam by 0.9% in the fourth quarter. Bank of Montreal Can now owns 105,928 shares of the company's stock valued at $2,525,000 after acquiring an additional 956 shares during the last quarter. 2Xideas AG acquired a new stake in Abcam in the fourth quarter valued at $16,691,000. Finally, HM Payson & Co. acquired a new stake in Abcam in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 11.82% of the company's stock.About Abcam
(Get Rating)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Read More
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.